MilliporeSigma acquires AmpTec

By The Science Advisory Board staff writers

January 7, 2021 -- MilliporeSigma has purchased messenger RNA (mRNA) firm AmpTec. The deal is expected to boost MilliporeSigma's ability to develop and manufacture mRNA for use in COVID-19 vaccines and treatments.

AmpTec's polymerase chain reaction (PCR)-based technology has benefits over other technologies for mRNA manufacturing, including better homogeneity, purity, and activity and improved performance, according to MilliporeSigma. As well, AmpTec's diagnostics business, which produces customized long RNAs and DNAs for in vitro diagnostics, will complement MilliporeSigma's own diagnostics business, it said.


Copyright © 2021 scienceboard.net
 


Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

 
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.